Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]OSI Pharmaceuticals"
Count: 73
Selected: 0
NCT IDTitle
NCT00116896Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors
NCT00116909A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy
NCT00088270A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer
NCT00073502Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer
NCT01247922Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
NCT01032070Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
NCT01010945Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
NCT00139620A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
NCT00072631Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00040183OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
NCT00036647OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00033241Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
NCT00373425A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
NCT00294762Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
NCT00085839Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2
NCT00294736A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
NCT00871923Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
NCT00570258Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
NCT01038856Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
NCT00497224Phase II Trial of Erlotinib in Advanced Pancreatic Cancer
NCT00385996Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer
NCT00283803Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
NCT01334710A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
NCT008410357 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
NCT01059305Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin
NCT00499655Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
NCT01003938Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
NCT01515137Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT01174043Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia
NCT01006096Erlotinib for Treatment of Psoriasis
NCT01567384A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies
NCT01427205Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT01299220Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)
NCT00739063Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer
NCT00085826A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients
NCT00072618Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients
NCT00046800Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
NCT00046787Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer
NCT00073489A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)
NCT00036036Study of CP-461 in Patients With Advanced Renal Cell Cancer
NCT00603356Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
NCT00513851Phase 1 Study of OSI-930 in Cancer Patients
NCT00166426Exisulind Versus Placebo After Surgical Removal of the Prostate
NCT00254410FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
NCT01154335Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
NCT00380029Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer
NCT01180959Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
NCT01257594EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
NCT01557959Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00304278Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)